Skip to main content

Animations

MJFF Publications

8061 - 8070 of 9030 Results
Title
Year
  • Year
  • 2023
  • 2021
  • 2024
  • 2023
  • 2025
  • 2024
  • 2020
  • 2013
  • 2020
  • 2016
  • Summary Details
    OPEN
    Title: Inactive S. aureus Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in human stem cell model of Parkinson’s disease
    Journal Name: Scientific Reports
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41598-023-45078-3
    Citation Count: 16
  • Summary Details
    OPEN
    Title: Blood–brain barrier permeability in Parkinson’s disease patients with and without dyskinesia
    Journal Name: Journal of Neurology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1007/s00415-021-10411-1
    Citation Count: 15
  • Summary Details
    OPEN
    Title: Neuroprotective Strategies and Cell-Based Biomarkers for Manganese-Induced Toxicity in Human Neuroblastoma (SH-SY5Y) Cells
    Journal Name: Biomolecules
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/biom14060647
    Citation Count: 7
  • Summary Details
    OPEN
    Title: MAPT Locus in Parkinson’s Disease Patients of Ashkenazi Origin: A Stratified Analysis
    Journal Name: Genes
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/genes15010046
    Citation Count: 2
  • Summary Details
    OPEN
    Title: An artificial intelligence-derived metabolic network predicts psychosis in Alzheimer’s disease
    Journal Name: Brain Communications
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1093/braincomms/fcaf159
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Randomized controlled trial of intermittent hypoxia in Parkinson’s disease: study rationale and protocol
    Journal Name: BMC Neurology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s12883-024-03702-3
    Citation Count: 7
  • Summary Details
    OPEN
    Title: Differences in the Presentation and Progression of Parkinson's Disease by Sex
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.28312
    Citation Count: 100
  • Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia
    2013
    Summary Details
    RESTRICTED
    Title: Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia
    Journal Name: Neuroscience Research
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.neures.2013.10.002
    Citation Count: 47
  • Summary Details
    OPEN
    Title: The Michael J. Fox Foundation’s Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease
    Journal Name: Cells
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/cells9081878
    Citation Count: 6
  • Summary Details
    OPEN
    Title: Novel method to ascertain chromatin accessibility at specific genomic loci from frozen brain homogenates and laser capture microdissected defined cells
    Journal Name: Neuroepigenetics
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.nepig.2016.03.001
    Citation Count: 0
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.